Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Gilead Sciences Inc announces topline results from three Phase3 clinical trials


Wednesday, 18 Dec 2013 08:32am EST 

Gilead Sciences Inc:Says it has announced topline results from three Phase3 clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analog polymerase inhibitor sofosbuvir (SOF) and the NS5A inhibitor ledipasvir (LDV). 

Company Quote

90.34
1.01 +1.13%
23 Jul 2014